surpass cvot tirzepatide SURPASS-CVOT shows delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize whole cardiometabolic systems. As outcome datasets grow AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide
Pay in 4 interest-free payments of $5.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27



01443-4/asset/1245bc8d-99c6-4ac1-b69b-8c0220ceb8fd/main.assets/gr1.jpg)























